医学
癌
子宫内膜癌
淋巴结
子宫切除术
病理
肿瘤科
癌症
内科学
作者
Hiroshi Yoshida,Masaya Uno,Keisuke Ogimoto,Mayumi Kobayashi-Kato,Yasuhito Tanase,Mitsuya Ishikawa,Tomoyasu Kato
出处
期刊:International Journal of Gynecological Pathology
[Ovid Technologies (Wolters Kluwer)]
日期:2023-02-21
卷期号:Publish Ahead of Print
标识
DOI:10.1097/pgp.0000000000000869
摘要
Endometrial cancer in transgender men is rare, and its histopathologic features remain unknown. A 30-yr-old transgender man with an intrauterine tumor, an ovarian mass, and a 2-yr history of testosterone use was referred to us for treatment. The presence of the tumors was confirmed via imaging, and the intrauterine tumor was identified as an endometrial endometrioid carcinoma via endometrial biopsy. The patient underwent hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and lymph node dissection. Pathologic examination revealed grade 3 endometrioid endometrial carcinoma, and the synchronous endometrial and ovarian tumors were collectively characterized as primary endometrial carcinoma. Metastatic carcinomas were discovered in both ovaries and the omentum, pelvic peritoneum, and a para-aortic lymph node. On immunohistochemistry, the tumor cells diffusely expressed p53, retained expression of PTEN, ARID1A, PMS2, and MSH6, and focally expressed estrogen receptors, androgen receptors, and NKX3.1. NKX3.1 was also expressed in glandular structures within the exocervical squamous epithelium. Prostate-specific antigen and prostatic acid phosphatase were focally positive. In conclusion, we describe a transgender man with NKX3.1-expressing endometrioid endometrial carcinoma who provides valuable suggestions regarding the effects of testosterone on endometrial cancer and appropriate gynecological care for transgender men.
科研通智能强力驱动
Strongly Powered by AbleSci AI